While best known for its use in cancer, radiotherapy (RT) can be used as a successful treatment for several nonmalignant diseases. Nonetheless, the use of non-oncological RT is uncommon, and its utilization varies from country to country.

There are many ongoing advances in the management of high risk and locally advanced prostate cancer, including concepts of systemic therapy intensification and de-escalation, dose escalation, and the use of biomarkers.

This case-based activity is designed to strengthen breast radiation therapy contouring skills. It emphasizes treatment planning strategies, practical anatomy, and variations in current contouring guidelines.

Cases Reviewed:

This activity is a case-based session with the goal of enhancing participants’ understanding of the moral theories underlying bioethics, and applying these theories to clinical cases that are relevant to radiation oncologists.

This activity provides a practical, case-based review of contemporary thoracic target and organ-at-risk delineation, with a particular focus on critical mediastinal and central thoracic structures.

With increasing systemic therapy options for gastrointestinal cancer patients, re-irradiation in gastrointestinal cancers is an increasingly important treatment strategy.

This activity focuses on the multidisciplinary care of liver and pancreatic cancer highlighting the role of radiation therapy.

This activity will evaluate contouring principles for patients with genitourinary malignancies and includes discussion about prostate cancers (definitive and post-operative) and bladder cancer.

The content was originally presented and recorded at the 2026 ASTRO Annual Refresher Course

Vaginal cuff brachytherapy (VBT) is a critical part of a radiation oncologist's practice and is routinely offered both at academic sites and within the community. However, in the modern era, many are stretched increasingly thin and have fewer resources to work with.

Use of SABR for selected patients with oligoprogressive (OP) prostate cancer and renal cell carcinoma (RCC) has been shown to have the potential to improve progression-free survival, extend the time to developing new metastatic lesions, and delay time to starting next systemic therapy without add

Pages

Subscribe to RSS - Sessions onDemand